Anish Thomas, MBBS, M.D.
Staff Clinician

Clinical interests: Translational clinical trials in lung cancer, mesothelioma and thymic cancers

Research interests: 1. Improve outcomes for small cell lung cancer by studying the evolution of chemotherapy resistance and the use of synthetic lethal approaches against DNA damage response pathways. 2. Immunotherapy of thoracic cancers - immunotoxins, vaccines and immune checkpoint inhibitors 3. Predictive markers for response to biologic therapy 4. Cancer drug development process and clinical trial designs

Areas of Expertise
small cell lung cancer, non-small cell lung cancer, thymic tumors, mesothelioma, translational research

Contact Info

Anish Thomas, MBBS, M.D.
Center for Cancer Research
National Cancer Institute
Building 10 Room 4-5330
Bethesda, MD 20892
301-451-8418
anish.thomas@mail.nih.gov

Clinical Interests: Multidisciplinary care of patients with lung cancer, mesothelioma and thymic cancers Research interests: 1. Immunothereapy of malignancy- immunotoxins, vaccines and immune checkpoint regulators 2. Predictive markers for response to biologic therapy 3. Anti-angiogenic and targeted therapeutics 4. Cancer drug development process and clinical trial designs

Scientific Focus Areas:
Cancer Biology, Clinical Research, Genetics and Genomics, Health Disparities, Immunology
  1. Molecular Profiling and Targeted Therapy for Advanced Thoracic Malignancies: a biomarker derived multi-arm, multi-histology phase II “basket” trial..
    Lopez-Chavez A, Thomas A (co-first author), Rajan A, Raffeld M, Morrow B, Kelly R, Carter CA, Guha U, Killian K, Lau CL, Abdullaev Z, Xi L, Pack S, Meltzer PS, Corless CL, Sandler A, Beadling C, Warrick A, Liewehr DJ, Steinberg SM, Berman A, Doyle A, Szabo E, Wang Y, Giaccone G
    J. Clin. Oncology. In press.: [ Journal Article ]
  2. Sunitinib in Patients with Chemotherapy Refractory Thymoma and Thymic Carcinoma: An Open Label Phase II Trial. .
    Thomas A, Rajan A, Berman A, Tomita Y, Brzezniak C, Lee M-J, Lee S, Ling A, Spittler AJ, Carter CA, Guha U, Wang Y, Szabo E, Meltzer P, Steinberg SM, Trepel JB, Loehrer PJ, Giaccone G
    Lancet Oncology. In press.: [ Journal Article ]
  3. Thomas A, Hassan R.
    Lancet Oncol.. 13: e301-310, 2012. [ Journal Article ]
  4. Characterization of fibroblast growth factor receptor 1 in small cell lung cancer.
    Thomas A, Lee J-H, Abdullaev Z, Park K, Pineda M, Saidkhodjaeva L, Miettinen M, Wang Y, Pack SD, Giaccone G
    J Thorac Oncol. 9(4): 567-571, 2014. [ Journal Article ]
  5. A Phase I/II Trial of Belinostat in Combination with Cisplatin, Doxorubicin and Cyclophosphamide in Thymic Epithelial Tumors: A Clinical And Translational Study.
    Thomas A, Rajan A, Szabo E, Tomita Y, Carter CA, Scepura B, Lopez-Chavez A, Lee MJ, Redon CE, Frosch A, Peer CJ, Chen Y, Piekarz RL, Steinberg SM, Trepel JB, Figg W, Schrump DS, Giaccone G
    Clin. Cancer Res.. In press.: [ Journal Article ]

Anish Thomas, MD is a medical oncologist who specializes in the treatment of thoracic cancers. He received his medical degree and postgraduate training in Internal Medicine from St. John's Medical College, Bangalore, India, following which he completed residency in Internal Medicine from State University of New York Upstate Medical University, Syracuse. He trained in Medical Oncology and Hematology at the Medical Oncology Branch of National Cancer Institute and the National Heart Lung and Blood Institute, respectively. His clinical care and research efforts are focused on the development of molecularly targeted therapies in thoracic cancers.

Research

Clinical Interests: Multidisciplinary care of patients with lung cancer, mesothelioma and thymic cancers Research interests: 1. Immunothereapy of malignancy- immunotoxins, vaccines and immune checkpoint regulators 2. Predictive markers for response to biologic therapy 3. Anti-angiogenic and targeted therapeutics 4. Cancer drug development process and clinical trial designs

Scientific Focus Areas:
Cancer Biology, Clinical Research, Genetics and Genomics, Health Disparities, Immunology

Publications

  1. Molecular Profiling and Targeted Therapy for Advanced Thoracic Malignancies: a biomarker derived multi-arm, multi-histology phase II “basket” trial..
    Lopez-Chavez A, Thomas A (co-first author), Rajan A, Raffeld M, Morrow B, Kelly R, Carter CA, Guha U, Killian K, Lau CL, Abdullaev Z, Xi L, Pack S, Meltzer PS, Corless CL, Sandler A, Beadling C, Warrick A, Liewehr DJ, Steinberg SM, Berman A, Doyle A, Szabo E, Wang Y, Giaccone G
    J. Clin. Oncology. In press.: [ Journal Article ]
  2. Sunitinib in Patients with Chemotherapy Refractory Thymoma and Thymic Carcinoma: An Open Label Phase II Trial. .
    Thomas A, Rajan A, Berman A, Tomita Y, Brzezniak C, Lee M-J, Lee S, Ling A, Spittler AJ, Carter CA, Guha U, Wang Y, Szabo E, Meltzer P, Steinberg SM, Trepel JB, Loehrer PJ, Giaccone G
    Lancet Oncology. In press.: [ Journal Article ]
  3. Thomas A, Hassan R.
    Lancet Oncol.. 13: e301-310, 2012. [ Journal Article ]
  4. Characterization of fibroblast growth factor receptor 1 in small cell lung cancer.
    Thomas A, Lee J-H, Abdullaev Z, Park K, Pineda M, Saidkhodjaeva L, Miettinen M, Wang Y, Pack SD, Giaccone G
    J Thorac Oncol. 9(4): 567-571, 2014. [ Journal Article ]
  5. A Phase I/II Trial of Belinostat in Combination with Cisplatin, Doxorubicin and Cyclophosphamide in Thymic Epithelial Tumors: A Clinical And Translational Study.
    Thomas A, Rajan A, Szabo E, Tomita Y, Carter CA, Scepura B, Lopez-Chavez A, Lee MJ, Redon CE, Frosch A, Peer CJ, Chen Y, Piekarz RL, Steinberg SM, Trepel JB, Figg W, Schrump DS, Giaccone G
    Clin. Cancer Res.. In press.: [ Journal Article ]

Biography

Anish Thomas, MD is a medical oncologist who specializes in the treatment of thoracic cancers. He received his medical degree and postgraduate training in Internal Medicine from St. John's Medical College, Bangalore, India, following which he completed residency in Internal Medicine from State University of New York Upstate Medical University, Syracuse. He trained in Medical Oncology and Hematology at the Medical Oncology Branch of National Cancer Institute and the National Heart Lung and Blood Institute, respectively. His clinical care and research efforts are focused on the development of molecularly targeted therapies in thoracic cancers.